Hibercell, Inc.

Ben Harrison

Nandita Bose

Jeremy Graff

Nadine Ottoson

Richard Huhn

Mark Uhlik

Jamie Lowe

This disclosure provides, in one aspect, dosing strategies for soluble &#x3b2;-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble &#x3b2;-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-&#x3b2;-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Growing community of inventors

Eagan, MN, United States of America

Ben Harrison